By 2025, above 2 lakh incidences of breast cancer and nearly 50 thousand of Ovarian Cancer incidences are estimated in India.
Familial breast cancer comprises approximately 20% to 30% of all breast cancers. BRCA1 and BRCA2 are two major genes associated with hereditary breast and ovarian cancer syndrome. Approximately 7 percent of breast cancer and 15 percent of ovarian cancer cases are caused by harmful changes (mutations) in the BRCA1 and BRCA2 genes[3,4,5].
The proteins produced by BRCA1 and BRCA2 ensure stability of cell’s genetic material. Mutation in BRCA1 and BRCA2 makes the cells likely to develop additional genetic changes that can lead to cancer
Specific inherited mutations in BRCA1 and BRCA2 most notably increase the risk of female breast and ovarian cancers, but they have also been associated with increased risks of several additional types of cancer
People who have inherited mutations in BRCA1 and BRCA2 tend to develop breast and ovarian cancers at younger ages than people who do not have these mutations
Hereditary Breast and Ovarian Cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (includes fallopian tube and primary peritoneal cancers), and to a lesser extent, other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 mutation. The exact cancer risks differ slightly depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.
Table 1: The impact of BRCA1 and BRCA2 mutation on risk of developing breast and ovarian cancer.
The MedGenome BRCA gene test is a blood test that helps assess your risk of developing cancer by detecting a potentially harmful change (mutation) in BRCA1 and BRCA2 genes. The blood sample goes to MedGenome lab for DNA analysis. It is very important to fill the Test Requisition Form (TRF) with accurate personal, clinical and family history (if present) details to enable effective interpretation of test results.
The time taken for generating a clinical report will be maximum of 3 weeks from receiving the samples in lab.
MedGenome offers a complimentary pre test and post test genetic counselling session with qualified professionals who offer unbiased insights about risk, occurrence or recurrence of genetic disorder in the individual/family
Assessment of hereditary cancer risk
Early detection for early intervention
2. Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res. 2008 Dec 15;14(24):7988-99.
3. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001 Mar;68(3):700-10.
4. Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, Hallberg E, Moore R, Thomas A, Lilyquist J, Feng B, McFarland R, Pesaran T, Huether R, LaDuca H, Chao EC, Goldgar DE, Dolinsky JS. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017 Sep 1;3(9):1190-1196.
5. LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T, Chen E, Gau CL, Palmaer E, Shoaepour K, Shah D, Speare V, Gandomi S, Chao E. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med. 2014 Nov;16(11):830-7.
6. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2016 Dec 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993- 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1247/
7. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian, V2.2019